Pharma Pulse 12/10/24: Did Industry Fumble the DSCSA Deadline? Operationalizing Bispecifics Resources & more

Did Industry Fumble the DSCSA Deadline?

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Resources and Education for Operationalizing Bispecifics

Panelists discuss how infrastructure including specialized staff training, updated protocols, enhanced monitoring systems, and comprehensive educational resources for health care providers is essential for institutions to successfully implement and optimize bispecific antibody therapies while ensuring patient safety and treatment efficacy.

Musk Flexes Muscle to Stop Infowars’ X Account Sale to The Onion

A clash among lawyers from Elon Musk’s X Corp., Alex Jones’ Infowars, and The Onion would normally be enough to pack a courtroom.

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Acadia Pharmaceuticals Inc. announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia’s CEO, and serve on the executive leadership team.

Loftware on LinkedIn

💊 How can innovations in label design improve patient outcomes and reduce medication errors? Loftware's Laura Johnson shares her insights with Pharmaceutical Executive: https://lnkd.in/ebNphYJh

#Pharma #Pharmaceuticals #LifeSciences #PatientSafety #Healthcare

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs